Skip to content

Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

Tony Mills at IAS 2015. Photo by Liz Highleyman, hivandhepatitis.com

Raltegravir appears to prevent mother-to-child HIV transmission during late pregnancy

Fatima Kakkar at IAS 2015. Photo by Liz Highleyman, hivandhepatitis.com

PrEP demo project finds the people at highest HIV risk generally take PrEP most consistently

Albert Liu at IAS 2015. Photo by Liz Highleyman, hivandhepatitis,com

Vancouver's treatment as prevention success is also due to harm reduction and addiction treatment

Evan Wood at IAS 2015 ©Marcus Rose/IAS

HIV self-testing may help the 'hard to reach' learn their status, but uncertainties remain

Frog Designs /iTEACH self-test packaging, KwaZulu-Natal. Image from presentation by Sheri Lippman at IAS 2015.

Peer-led network intervention substantially lowers HIV infections in people who use drugs in Ukraine

Image from the Insite Supervised Injection Centre Media Field Trip photo ©Colin Askey/IAS

Gay youth PrEP study finds good retention and reasonable adherence

Sybil Hosek at IAS 2015 photo ©Marcus Rose/IAS

Giving people information about HIV treatment as prevention lessens stigma and increases testing rates

An educator using the study infographic in the field. Image supplied by Laura Derksen.

New NNRTI doravirine suppresses HIV as well as efavirenz but with fewer central nervous system side-effects

Dr José Gatell at IAS 2015. Photo by Liz Highleyman, hivandhepatitis.com